Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 2/20 | 0.55 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3326047 | 1.00 | CACNA1G (0.55) | CACNA1GCACNA1HMAPTSIGMAR1PDK1 | |
| SCHEMBL3325442 | 0.82 | MAPT (0.47) | CACNA1GCACNA1HMAPTSIGMAR1PDK1 | |
| SCHEMBL6742274 | 0.81 | MAPT (0.66) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL6742277 | 0.81 | MAPT (0.66) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL3326662 | 0.81 | MAPT (0.51) | CACNA1GCACNA1HMAPTSIGMAR1PDK1 | |
| SCHEMBL4048121 | 0.79 | MAPT (0.68) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL6741206 | 0.79 | MAPT (0.68) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL27979641 | 0.79 | MAPT (0.68) | MAPTSIGMAR1PDK1PDK2PDK3 | |
| SCHEMBL538067 | 0.76 | LTA4H (0.48) | CACNA1GCACNA1HMAPTSIGMAR1 | |
| SCHEMBL597548 | 0.74 | MAPT (0.48) | CACNA1GCACNA1HMAPTSIGMAR1PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183255-B2 | N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors | PFIZER, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183255-B2 | N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors | PFIZER, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | DPP3, IAPP, GPR119 | CACNA1G 3565/4885CACNA1H 3107/4885MAPT 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.